Latest Product Innovation News

Page 1 of 67
The a2 Milk Company says China-label infant formula offtake has recovered to about half of pre-disruption levels, but expects total IMF sales to remain broadly flat in FY27. Group revenue and EBITDA are still forecast to grow, with earnings heavily weighted to the second half.
Victor Sage
Victor Sage
19 Nov 2026
Nike has laid out a five-year recovery plan targeting US$5 billion in incremental revenue by fiscal 2031, but the near-term picture remains difficult. Fiscal 2027 revenue is still expected to fall by a high-single-digit percentage, with restructuring costs weighing on earnings.
Logan Eniac
Logan Eniac
18 Nov 2026
BCAL Diagnostics has completed clinical validation for BREASTESTplus 2 across all breast densities and is targeting a November launch, while expanding Avantect Multicancer access. The commercial push comes alongside $1.895 million in quarterly operating cash outflows, only $580,000 in cash at quarter end and a growing strategic stake in Genetic Signatures.
Ada Torres
Ada Torres
30 Oct 2026
Bubs Australia has expanded its US footprint to more than 12,000 stores after securing permanent FDA authorisation, but quarterly revenue fell 9.8% and operating cash outflow increased. The company ended September with A$13.4 million of available liquidity, equivalent to 2.2 quarters at the reported cash-burn rate.
Victor Sage
Victor Sage
29 Oct 2026
Sea Forest lifted first-quarter revenue 67% to A$3.4 million and generated a small operating cash inflow as it transitioned to a new distribution arrangement with Teys Australia. The agreement carries an indicative target of 480,000 cattle by June 2027, but the volume is not guaranteed and remains subject to implementation conditions.
Victor Sage
Victor Sage
28 Oct 2026
Cochlear has reaffirmed FY27 underlying net profit guidance of $330 million to $350 million after a disappointing FY26, while pointing to strong Nexa adoption and progress on fully implantable hearing technology. The company is cutting fixed costs and expanding medical referral pathways as it seeks to convert a large pool of untreated adult hearing loss into growth.
Victor Sage
Victor Sage
26 Oct 2026
Codan has set a first-half FY27 NPAT floor of $162 million after delivering record FY26 results, while targeting Communications revenue growth at the upper end of its 30% to 40% range. The company is benefiting from exceptional demand for unmanned systems, although visibility in conflict markets remains limited beyond the near term.
Sophie Babbage
Sophie Babbage
20 Oct 2026
Clover Corporation has delivered record FY26 revenue of $97.4 million and a 50% lift in attributable profit, while raising its fully franked final dividend to 1.25 cents per share. The result comes alongside a planned chair transition, with Ian Glasson set to replace retiring chair Rupert Harrington after the 2026 AGM.
Victor Sage
Victor Sage
23 Sept 2026
James Hardie has raised its FY27 Free Cash Flow target to at least US$600 million and expects to deliver its US$125 million cost synergy target roughly a year early. The company also outlined a 4% to 7% annual organic growth ambition above market, while targeting net leverage below 2.0x by Q2 FY28.
Victor Sage
Victor Sage
16 Sept 2026
Bubs Australia has secured permanent US FDA authorisation for three infant formula products, removing a regulatory barrier in the company’s largest market. The approval supports possible portfolio expansion and contract manufacturing, but the presentation contains no new earnings guidance or quantified financial benefit.
Victor Sage
Victor Sage
10 Sept 2026
Australian Bond Exchange Holdings (ASX: ABE) reported a 47% revenue increase to $3.55 million for FY26, cutting its loss after tax by nearly two-thirds to $1.51 million amid ongoing going concern uncertainty.
Claire Turing
Claire Turing
1 Sept 2026
SportsHero Limited reported a dramatic surge in revenue to AU$1.05 million for FY26, driven by new telco partnerships and the HeroPlay gaming platform launch, while losses increased 29% as the company ramped up marketing and development costs.
Sophie Babbage
Sophie Babbage
31 Aug 2026

Browse the archive

Full archive